Related Experiment Video

Updated: Aug 13, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

Lipid Metabolic Alterations in KRAS Mutant Tumors: Unmasking New Vulnerabilities for Cancer Therapy

Maria Saliakoura1, Georgia Konstantinidou1

  • 1Institute of Pharmacology, Inselspital, INO-F, University of Bern, 3010 Bern, Switzerland.

International Journal of Molecular Sciences
|January 21, 2023
PubMed

Insights

Mutated KRAS (Kirsten rat sarcoma viral oncogene homolog) drives aggressive tumors by altering lipid metabolism. Understanding these changes is key to developing new therapies for KRAS-driven cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Metabolic Research

Background:

  • KRAS mutations are prevalent in aggressive cancers.
  • Mutated KRAS promotes tumor cell survival through metabolic reprogramming.
  • Current therapies for KRAS-driven tumors have limited efficacy.

Purpose of the Study:

  • To review lipid metabolic alterations in KRAS-driven tumors.
  • To elucidate the unique metabolic characteristics of these cancers.
  • To identify potential novel therapeutic targets.

Main Methods:

  • Literature review of recent studies on KRAS and lipid metabolism.
  • Analysis of molecular mechanisms underlying metabolic rewiring.
  • Synthesis of data on tumor adaptation and survival strategies.

Main Results:

  • KRAS mutations induce significant changes in cellular lipid metabolism.
  • These metabolic adaptations support cancer cell survival in challenging environments.
  • Specific lipid pathways are critical for KRAS-driven tumor phenotypes.

Conclusions:

  • Targeting lipid metabolism represents a promising therapeutic strategy for KRAS-driven cancers.
  • Further research into KRAS-mediated metabolic regulation is crucial.
  • Identifying specific metabolic vulnerabilities could lead to effective treatments.
Keywords:
KRAS-driven tumorscancer therapylipid metabolismtumor vulnerabilities

More Related Videos

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

2.5K
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.2K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.1K